Demographics and baseline characteristics
| Cohort 1 (n=1456) | Cohort 1: H pylori −ve (n=738*) | Cohort 1: H pylori +ve (n= 571*) | Cohort 2 (n=333) | |
|---|---|---|---|---|
| *Helicobacter pylori status unknown in 147 patients. | ||||
| †In these patients NSAID medication data were too incomplete to derive a DDD of NSAID. | ||||
| OA, osteoarthritis RA, rheumatoid arthritis; GU, gastric ulcer; DU, duodenal ulcer; NSAIDs, non-steroidal anti-inflammatory drugs; DDD, defined daily dose. | ||||
| Age (y) | ||||
| Mean (SD) | 58 (12) | 57 (13) | 58 (12) | 57 (13) |
| Range | 20–85 | 20–85 | 23–85 | 22–85 |
| Female | 938 (64%) | 68% | 61% | 196 (59%) |
| Smokers | 333 (23%) | 21% | 25% | 85 (26%) |
| Previous peptic ulcer | 429 (29%) | 27% | 35% | 98 (29%) |
| Previous dyspepsia | 1143 (79%) | 77% | 82% | 284 (85%) |
| H pylori status | ||||
| Unknown | 147 (10%) | 43 (13%) | ||
| Negative | 738 (51%) | 100% | 192 (58%) | |
| Positive | 571 (39%) | 100% | 98 (29%) | |
| Arthritic disease | ||||
| RA | 583 (40%) | 43% | 40% | 140 (42%) |
| OA | 606 (42%) | 39% | 42% | 145 (44%) |
| Other | 218 (15%) | 15% | 15% | 39 (12%) |
| Combination | 49 (3%) | 3% | 3% | 9 (3%) |
| Type of lesion | ||||
| 0–10 erosions | — | — | — | 150 (45%) |
| GU | 581 (40%) | 40% | 39% | 76 (23%) |
| GU+DU | 55 (4%) | 3% | 5% | 11 (3%) |
| DU | 304 (21%) | 16% | 27% | 40 (12%) |
| Erosions only (≥11) | 516 (35%) | 41% | 30% | 56 (17%) |
| NSAIDs (DDD) | ||||
| Uncertain† | 149 (10%) | 12% | 9% | 45 (14%) |
| 0–1 | 561 (39%) | 34% | 45% | 112 (34%) |
| >1 | 746 (51%) | 54% | 46% | 176 (53%) |
| Steroids | 250 (17%) | 20% | 15% | 54 (16%) |